JWH-309 explained

JWH-309 (naphthalen-1-yl-(5-naphthalen-1-yl-1-pentylpyrrol-3-yl)methanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB₁ (K_i = 41 ± 3nM) and CB₂ (K_i = 49 ± 7nM) receptors, displaying a slight selectivity for the former. JWH-309 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB₁ receptor.^[1]

Legality

In the United States JWH-309 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-309.^{[2] [3] [4]}

In Canada, JWH-309 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.

In the United Kingdom, JWH-309 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.

See also

• List of JWH cannabinoids
• Synthetic cannabinoid

Notes and References

1. Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR . 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors . Bioorganic & Medicinal Chemistry Letters . 16 . 20 . 5432–5 . October 2006 . 16889960 . 10.1016/j.bmcl.2006.07.051 .
2. Web site: The 2020 Florida Statutes . www.leg.state.fl.us . 20 August 2021.
3. Web site: Arizona Revised Statutes Title 13. Criminal Code § 13-3401 . www.azleg.gov . 20 August 2021.
4. Web site: California Code, Health and Safety Code - HSC § 11357.5 . Findlaw.